A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
We are a commercial-stage biotechnology company focused on improving the lives of patients by developing and commercializing therapeutic innovations that improve medical care. Our advanced science, patented technologies, and innovative approach to drug discovery and development have allowed us to create and commercialize a portfolio of products that aim to advance the standard of care for acute care and oncology patients. Acute Care Product Portfolio ZYNRELEF is a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam.
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 155M | 155M | 144M | 127M | 108M | - |
| Net Income | -20M | -20M | -14M | -111M | -182M | -221M |
| EPS | $-0.12 | $-0.12 | $-0.09 | $-0.80 | $-1.67 | $-2.24 |
| Free Cash Flow | -28M | -28M | -24M | -60M | -149M | -206M |
| ROIC | -10.9% | -8.9% | -11.7% | -95.7% | -111.8% | -97.4% |
| Gross Margin | 73.3% | 73.3% | 73.2% | 48.8% | 49.0% | - |
| Debt/Equity | 2.28 | 2.28 | -4.54 | -4.57 | 11.60 | 2.06 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | -2.5M | -2.5M | -12M | -111M | -175M | -218M |
| Operating Margin | -1.6% | -1.6% | -8.0% | -87.1% | -162.2% | - |
| ROE | -140.9% | -140.9% | - | - | -1341.2% | -284.5% |
| Shares Outstanding | 168M | 168M | 151M | 138M | 109M | 99M |
HERON THERAPEUTICS, INC. /DE/ passes 1 of 9 quality checks, indicating weak fundamentals.
The company's 5-year average gross margin is 61.1%.
HERON THERAPEUTICS, INC. /DE/ (HRTX) has a 5-year average return on invested capital (ROIC) of -65.1%. This is below average and may indicate limited pricing power.
HERON THERAPEUTICS, INC. /DE/ (HRTX) has a market capitalization of $153M. It is classified as a small-cap stock.
HERON THERAPEUTICS, INC. /DE/ (HRTX) does not currently pay a regular dividend.
HERON THERAPEUTICS, INC. /DE/ (HRTX) operates in the Pharmaceutical Preparations industry, within the Healthcare sector.
HERON THERAPEUTICS, INC. /DE/ (HRTX) reported annual revenue of $155 million in its most recent fiscal year, based on SEC EDGAR filings.
HERON THERAPEUTICS, INC. /DE/ (HRTX) has a net profit margin of -13.0%. The company is currently unprofitable.
HERON THERAPEUTICS, INC. /DE/ (HRTX) generated $-28 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
HERON THERAPEUTICS, INC. /DE/ (HRTX) has a debt-to-equity ratio of 2.28. This indicates higher leverage, which may increase financial risk.
HERON THERAPEUTICS, INC. /DE/ (HRTX) reported earnings per share (EPS) of $-0.12 in its most recent fiscal year.
HERON THERAPEUTICS, INC. /DE/ (HRTX) has a return on equity (ROE) of -140.9%. A negative ROE may indicate losses or negative equity.
HERON THERAPEUTICS, INC. /DE/ (HRTX) has a 5-year average gross margin of 61.1%. This high margin suggests strong pricing power and a potential competitive moat.
The Ledger Terminal provides 15 years of financial data for HERON THERAPEUTICS, INC. /DE/ (HRTX), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
HERON THERAPEUTICS, INC. /DE/ (HRTX) has a book value per share of $0.09, based on its most recent annual SEC filing.
No recent press releases.